Arrow sights more direct US sales with Horizon buy
This article was originally published in Clinica
Disposable catheter producer Arrow International says that 84% of its US sales will be generated through its own direct distribution once new acquisition Stepic Medical is fully integrated. Arrow, of Reading, Pennsylvania, has agreed to buy Stepic, which has been acting as its New York/New Jersey distributor since 1977, from Horizon Medical Products for $12.7m cash and $700,000 of retained assets.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.